Infliximab early treatment significantly reduces surgery and further treatment needs in Crohn's disease patients, according to a UK study.
Early treatment with infliximab significantly reduces the need for surgery and further treatment in Crohn's disease patients, according to a study involving 386 newly diagnosed patients from 40 hospitals across the UK. Researchers at the University of Cambridge found that prescribing the advanced therapy within two years of diagnosis led to improved outcomes, with 80% of patients experiencing controlled symptoms after a year, compared to 15% of those following a standard regime.
February 22, 2024
5 Articles